Checkpoint Inhibition in Lung Cancer with Poor Performance Status
Can checkpoint immunotherapy provide safe, meaningful benefit for people with lung cancer and poor performance status?
Following this cluster helps show whether reported responses in individual patients are supported by broader evidence. That matters when treatment decisions involve people often underrepresented in research.
Where it stands now
Main bottleneck
The bounded evidence includes a three-patient case series and a planned systematic review and meta-analysis; it does not yet establish how consistently immunotherapy works or how safe it is for this group.
Watch next
A verifiable report of the systematic review and meta-analysis, with its findings on effectiveness and safety in NSCLC patients with ECOG performance status 2 or higher.
Progress timeline
How the evidence has changed over time.
2021 · 2 updates
- A striking return of function in three people with advanced lung cancerResearch note 1 of 2 · Source date 2021-01-01
- How daily function related to response and serious harms during lung cancer immunotherapyPartly supportedResearch note 2 of 2 · Source date 2021-06-06
Since the previous research note · Partly supported
Track continuity
Since the previous research note: A striking return of function in three people with advanced lung cancer
Previous expectation: Larger studies might clarify whether checkpoint treatment offers meaningful benefit with acceptable harms to patients whose daily function is very limited.
What this study adds: This 2021 synthesis pools 67 studies and finds lower response and shorter survival in the poorer-function group, while its severe adverse-event estimate shows no clear group difference. It still cannot determine treatment benefit relative to another care option.
Current research note
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.